Orthopaedic surgery in haemophilic patients with inhibitors: an overview.
Our experience and a review of the literature on inhibitors have shown that, with the availability of recombinant factor VIIa (rFVIIa), haemophilic patients with high inhibitor titres requiring elective orthopaedic surgery can undergo such surgery with a high expectation of success. The advent of rFVIIa has made major elective orthopaedic surgery possible in haemophilic patients with high-titre inhibitors, resulting in an improved quality of life. Recombinant FVIIa appears to be an efficient haemostatic product for surgery in patients suffering from haemophilia A and B with inhibitors. The series of major elective orthopaedic surgical procedures using rFVIIa (n=53) is the largest ever reported in haemophilic patients with inhibitors, despite the long-standing presence of other treatment modalities, such as high-dose human factor VIII (FVIII), porcine FVIII (n=8), and prothrombin complex concentrates/activated prothrombin complex concentrates (n=9). Thorough analysis of each case as part of a multidisciplinary team will allow us to perform elective orthopaedic procedures in patients with inhibitors.
Hvid
I
I
Children's Orthopaedics, Department of Orthopaedics E, University Hospital of Aarhus, Denmark. akh-ihvid@aaa.dk
Rodriguez-Merchan
E C
EC
D001685:Biological Factors / Q000276:immunology / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D006467:Hemophilia A / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007518:Isoantibodies; D019637:Orthopedic Procedures; D011994:Recombinant Proteins / Q000627:therapeutic use
D001685:Biological Factors; D007518:Isoantibodies; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa